Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

R Paul Edick


  • Director at Milestone Pharmaceuticals Inc. (MIST), 2019-05-09
  • See Remarks at Xeris Pharmaceuticals Inc (XERS), 2019-03-12
  • Director at Iterum Therapeutics Plc (ITRM), 2018-08-27
  • Director at Pdl Biopharma Inc. (PDLI), 2018-06-12
  • Director at Sucampo Pharmaceuticals Inc. (SCMP), 2018-02-13
  • Director at Neos Therapeutics Inc. (NEOS), 2017-07-05
  • Director at Newlink Genetics Corp ((NLNK)), 2017-05-16
  • Chief Executive Officer at Durata Therapeutics Inc. (DRTX), 2014-11-18
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
XERS $9.12 30,000 Officer, Director 155,000 2019-03-11 Filing
ITRM $10.44 500 Director 25,236 2018-08-23 Filing
DRTX $15.23 3,000 Officer, Director 45,636 2014-06-12 Filing
DRTX $7.09 3,000 Officer, Director 43,136 2013-05-20 Filing
DRTX $9.00 500 Officer, Director 40,136 2012-07-24 Filing